. 2022; 39(3): 206-210 | DOI: 10.4274/tjh.galenos.2022.2022.0193 | |||
Türkiye Akademik CAR-T Hücre (ISIKOK-19) Klinik Çalışması Ön Raporu: Ürün Karakterizasyonu ve Klinik Uygulama SonuçlarıEbru Erdoğan1, Koray Yalçın2, Cansu Hemşinlioğlu3, Aslıhan Sezgin1, Utku Seyis3, Derya Dilek Kancağı3, Cihan Taştan4, Bulut Yurtsever3, Raife Dilek Turan3, Didem Çakırsoy3, Selen Abanuz3, Gözde Sır Karakuş3, Muhammer Elek3, Hüseyin Saffet Beköz5, Ali İhsan Gemici5, Deniz Sargın5, Mutlu Arat6, Burhan Ferhanoğlu7, Ebru Pekgüç7, Serdar Örnek7, Deram Büyüktaş7, Nur Birgen3, Siret Ratip1, Ercüment Ovalı31Acıbadem Altunizade Hospital, Hematology Unit, İstanbul, Turkey2Acıbadem Labcell Cellular Therapy Center, İstanbul, Turkey; Bahçeşehir University Medical Park Göztepe Hospital, Pediatric Bone Marrow Transplantation Unit, İstanbul, Turkey 3Acıbadem Labcell Cellular Therapy Center, İstanbul, Turkey 4Acıbadem Labcell Cellular Therapy Center, İstanbul, Turkey; Üsküdar University, Molecular Biology and Genetics Department of Transgenic Cell Technologies and Epigenetic Application and Research Center (TRGENMER), İstanbul, Turkey 5Medipol University Faculty of Medicine, Hematology Unit, İstanbul, Turkey 6İstanbul Florence Nightingale Hospital, Hematology Unit, İstanbul, Turkey 7VKV American Hospital, Hematology Unit, İstanbul, Turkey Amaç: Kimerik antijen reseptör T (CAR-T) hücre uygulamaları B-hücreli malignitelerin tedavisinde etkili olmaktadır. CAR-T hücre uygulamalarının sonuçları umut vaadedici olsa da, ticari CAR-T ürünlerinin yükek maliyetleri nedeniyle ulaşılabilirlik açısından ciddi sorunlar yaşanmaktadır. Bu ön raporda, Türkiye’deki ilk akademik CAR-T hücre çalışmasının üretim ve klinik uygulama sonuçları sunulmuştur. Preliminary Report of the Academic CAR-T (ISIKOK-19) Cell Clinical Trial in Turkey: Characterization of Product and Outcomes of Clinical ApplicationEbru Erdoğan1, Koray Yalçın2, Cansu Hemşinlioğlu3, Aslıhan Sezgin1, Utku Seyis3, Derya Dilek Kancağı3, Cihan Taştan4, Bulut Yurtsever3, Raife Dilek Turan3, Didem Çakırsoy3, Selen Abanuz3, Gözde Sır Karakuş3, Muhammer Elek3, Hüseyin Saffet Beköz5, Ali İhsan Gemici5, Deniz Sargın5, Mutlu Arat6, Burhan Ferhanoğlu7, Ebru Pekgüç7, Serdar Örnek7, Deram Büyüktaş7, Nur Birgen3, Siret Ratip1, Ercüment Ovalı31Acıbadem Altunizade Hospital, Hematology Unit, İstanbul, Turkey2Acıbadem Labcell Cellular Therapy Center, İstanbul, Turkey; Bahçeşehir University Medical Park Göztepe Hospital, Pediatric Bone Marrow Transplantation Unit, İstanbul, Turkey 3Acıbadem Labcell Cellular Therapy Center, İstanbul, Turkey 4Acıbadem Labcell Cellular Therapy Center, İstanbul, Turkey; Üsküdar University, Molecular Biology and Genetics Department of Transgenic Cell Technologies and Epigenetic Application and Research Center (TRGENMER), İstanbul, Turkey 5Medipol University Faculty of Medicine, Hematology Unit, İstanbul, Turkey 6İstanbul Florence Nightingale Hospital, Hematology Unit, İstanbul, Turkey 7VKV American Hospital, Hematology Unit, İstanbul, Turkey Objective: Chimeric antigen receptor T (CAR-T) cell therapies have already made an impact on the treatment of B-cell malignancies. Although CAR-T cell therapies are promising, there are concerns about commercial products regarding their affordability and sustainability. In this preliminary study, the results of the first production and clinical data of an academic CAR-T cell (ISIKOK-19) trial in Turkey are presented. Ebru Erdoğan, Koray Yalçın, Cansu Hemşinlioğlu, Aslıhan Sezgin, Utku Seyis, Derya Dilek Kancağı, Cihan Taştan, Bulut Yurtsever, Raife Dilek Turan, Didem Çakırsoy, Selen Abanuz, Gözde Sır Karakuş, Muhammer Elek, Hüseyin Saffet Beköz, Ali İhsan Gemici, Deniz Sargın, Mutlu Arat, Burhan Ferhanoğlu, Ebru Pekgüç, Serdar Örnek, Deram Büyüktaş, Nur Birgen, Siret Ratip, Ercüment Ovalı. Preliminary Report of the Academic CAR-T (ISIKOK-19) Cell Clinical Trial in Turkey: Characterization of Product and Outcomes of Clinical Application. . 2022; 39(3): 206-210 Sorumlu Yazar: Koray Yalçın, Türkiye |
|